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M A N U S C R I P T A C C E P T E D M A N U S C R I P T A C C E P T E D Introduction
Atrial fibrillation (AF) is common among the elderly, and increases the risks for stroke and death 1 .
The prevalence of AF increases with age, affecting 10% of those aged 80 years and 18% of those age >85 years 2 . The management of AF in elderly patients is of paramount importance, not only because of its increasing prevalence with age, but also because increasing age is an independent risk factor for ischemic stroke 3 .
The use of oral anticoagulants (OAC) reduces stroke by 64% and all-cause mortality by 26%, compared with controls 4 . Thus, several sets of guidelines recommend that elderly AF patients aged over 75 years be offered OAC 5 . However, OAC therapy remains widely under-used in clinical practice, and only 15% to 50% of eligible elderly patients are prescribed warfarin therapy [6] [7] [8] [9] .
The management of OAC in the extreme elderly (age ≥85 years of age) patients is challenging due to the need to balance carefully the risk of thromboembolism with that of hemorrhage. To date, clinical trials have not specifically targeted extreme elderly patients, and most study subjects are not representative of the extreme elderly. Indeed, data on clinical characteristics and outcomes in the extreme elderly are limited, with no previous publications from Asia, including Japan. Our aim was to evaluate the clinical characteristics, including the status of OAC therapy and outcomes, in extreme elderly AF patients in 'real-world' clinical practice. 
Methods
The Fushimi AF Registry is a community-based prospective survey of AF patients who visited the participating medical institutions in Fushimi district, Kyoto, Japan, which is a densely populated urban area with a total population of 283,000. The detailed study design, patient enrollment, definition of the measurements, and subjects' baseline clinical characteristics of the Fushimi AF Registry have been previously described (UMIN Clinical Trials Registry: UMIN000005834) 10, 11 .
This study was conducted in accordance with the amended Declaration of Helsinki. The study protocol was approved by the ethical committees of the National Hospital Organization Kyoto Medical Center (the approval number 14-033). Since the present research involves an observational study not using human biological specimens, written informed consent was not obtained from each patient according to the ethical guidelines for epidemiological research issued by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan.
Age data were collected at the time of entry into the registry. We defined the extreme elderly as those aged ≥85 years. We compared the background and the incidence of clinical events during a mean follow-up of 2.0 years (739 days) between the extreme elderly group and others (aged ≤74 years and aged 75-84 years). Chronic kidney disease (CKD) was diagnosed if there was persistent proteinuria or if estimated glomerular filtration rate was <60 mL/min/1.73 m 2 for more than 3 for elderly patients (≥70 years old) and 2.0~3.0 for younger patients (<70 years old) 13 . Anti-platelet drugs (APD) included aspirin, clopidogrel, ticlopidine and cilostazol.
The CHADS 2 scoring adds together the points that correspond to the following conditions: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack (two points) 14 . The CHA 2 DS 2 -VASc scoring is a refinement of the CHADS 2 score and extends it by including additional common stroke risk factors: age (patients ≥75 years old get two points and patients 65-74 years old get one point), vascular disease and female gender 15 . We consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was confirmed by computed tomography or magnetic resonance imaging. Major bleeding was defined as a reduction in the hemoglobin level by at least 2 g/dL, transfusion of at least 2 units of blood or symptomatic bleeding in a critical area or organ, following the definition by International Society on Thrombosis and Haemostasis 17 .
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD). Categorical variables are presented as absolute numbers and percentages. We compared continuous variables between the 2 groups using Student's t-test or Wilcoxon rank sum test on the basis of the distribution. Comparisons of the continuous variables of baseline data between the 3 groups were performed by 1-way analysis of variance (ANOVA). We compared categorical variables of baseline data using the Chi-square test when appropriate; otherwise, we used Fisher's exact test. Kaplan-Meier analysis was used to estimate event-free survival, and the log-rank test was used to compare survival across the groups.
The univariate Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the incidence of clinical events between each age group. A 2-sided P-value <0.05 was considered statistically significant. All statistical analyses were performed with JMP10.0 (SAS Institute Inc., Cary, NC, USA).
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Results
Of 3,666 patients who were enrolled into the Fushimi AF Registry by the end of July 2013, follow-up data (collected every year) were available for 3,304 patients (90.1%) by the end of July 2014. The age distribution in the entire cohort is shown in Figure 1A . The extreme elderly group accounted for 14.5% (479 patients).
The extreme elderly group was more often female (65.8%), with low body weight (49.0 kg) and low body mass index (21.1), and had many co-morbidities such as heart failure, coronary heart disease and chronic kidney disease ( Table 1) . Mean CHADS2 scores were as follows; 1.35 at age ≤74 years, 2.61 at age 75-84 years and 2.83 at age ≥85 years (p<0.01). Mean HAS-BLED score were as follows; 1.51 at age ≤74 years, 1.88 at age 75-84 years and 1.77 at age ≥85 years (p<0.01).
Patients whose HAS-BLED scores were ≥3 accounted for 18% (371 patients). Figure 1B shows the status of OAC and APD prescription according to age. OAC was used most frequently in those aged 75-79 years (60.1%) and its use decreased gradually with increasing age. On 30% to 50% in all of the CHADS 2 subpopulations, with a weak association with the CHADS 2 score.
In contrast, APD prescription rates were similar in all of the CHADS 2 subpopulations, for both the extreme elderly group and others.
The status of OAC therapy in each age group is shown in Table 1 . Warfarin was the major OAC used in the study period. The prescription rates of OAC were as follows; 51.2% at age ≤74 years, 60.0% at age 75-84 years and 41.3% at age ≥85 years (p<0.01). The intensities of warfarin control as measured by mean PT-INR values at enrollment were comparable among the age groups (1.82 at age Figure   2 . As shown in Table 2 , the annual incidence rates of stroke/SE, all-cause death and major bleeding in the extreme elderly group were 5. CI 2.84-4.25, p<0.01), and a higher incidence of the composite of stroke/SE and all-cause death (HR 3.20, 95% CI 2.66-3.84, p<0.01), compared with those aged ≤84 years. The incidence of major bleeding was not significantly different (HR 1.40, 95% CI 0.78-2.36, p=0.25, compared with those aged ≤84 years).
Baseline characteristics, co-morbidities, medications and incidence rates of endpoints in the extreme elderly according to OAC use at baseline are shown in Table 3 . The mean CHADS 2 score and CHA 2 DS 2 -VASc score were comparable between those with and without OAC (CHADS 2 score: 2.95 vs. 2.74, p=0.06; CHA 2 DS 2 -VASc score: 4.66 vs. 4.59, p=0.55), and so were the major co-morbidities, except for a higher prevalence of previous stroke in those with OAC (36.4% vs.
23.5%, p<0.01). The mean HAS-BLED score was also comparable between those with and without OAC (1.73 vs. 1.80, p=0.53).
Kaplan-Meier curves for stroke/SE and all-cause death, stroke/SE, all-cause death and major bleeding between patients taking and not taking OAC in the extreme elderly group are shown in Figure 3 . The incidence rates of the composite of stroke/SE and all-cause death in extreme elderly patients were comparable between those with and without OAC (HR 0.94, 95% CI 0.69-1.28, p=0.71). The incidences of stroke/SE in those taking OAC were higher than those not taking OAC (HR 2.70, 95% CI 1.42-5.41, p<0.01), and the mortality rate was marginally lower, but this was not statistically significant (HR 0.75, 95% CI 0.53-1.06, p=0.11). The incidences of major bleeding in those with OAC were comparable to that in those without OAC (HR 0.88, 95% CI 0. 
Discussion
This is one of the largest community-based prospective cohorts of elderly Asian subjects with AF, where we describe the clinical characteristics and outcomes of Japanese extreme elderly (age ≥85) patients with AF in 'real-world' clinical practice. We found an under-use of OAC, but a high risk of stroke/SE and mortality, alongside a similar risk of bleeding. Second, there was a paradoxical finding that the incidence of stroke/SE was higher in extreme elderly patients with OAC compared to those without OAC use.
Despite the proven benefit of OAC for preventing stroke in patients with AF, its under-use has been reported, particularly among those aged ≥80 years 6 . Our study shows that the proportion of usage of OAC decreases gradually as patients age, and only 41.3% of extreme elderly patients were taking OAC. Our study also shows that extreme elderly patients with AF had a weak association with OAC prescription according to stroke risk scores, again consistent with a previous report from Japan showing modest relationship between CHADS 2 risk score and warfarin use 18 . The decision to prescribe long-term OAC therapy in extreme elderly patients with AF remains challenging because of the lack of clinical data concerning the risk of both thromboembolism and bleeding.
Thromboembolism in the extreme elderly with AF
Yamashita, et al. The extreme elderly with AF (CHEST-15-1095) 13 One reported study found that the overall annual incidence of ischemic stroke among elderly Chinese AF patients aged ≥80 years was as high as 11.3% per year 19 . Our study showed that the incidence of stroke/SE was 5.1 per 100 person-years in Japanese extreme elderly patients with AF, which may reflect differences in study populations (hospitalized vs. community setting) and OAC use.
The present study demonstrates the paradoxical finding that the incidence of stroke/SE was higher in extreme elderly patients with OAC than in those without OAC use. It was unlikely that hemorrhagic stroke was more common in the OAC-treated group (0.7 per 100 person-years in patients with OAC vs. 0.6 in patients without OAC). CHADS 2 and CHA 2 DS 2 -VASc scores were comparable between those with and without OAC, but history of stoke were more frequent in those with OAC (36.4% vs, 23.5%; p<0.01), and other unidentified risk factors may have been associated.
Insufficient intensity of warfarin (under-dose of warfarin) may also have been the underlying reason for the higher incidence of stroke in OAC-treated patients. The mean PT-INR value was not particularly low in the extreme elderly, but PT-INR values were missing in more than 30% of patients in the extreme elderly. Particular care is therefore needed when managing this elderly patient age group, given their high stroke risk overall, especially the need for careful thromboprophylaxis and treatment adherence to optimize stroke prevention in these patients. Indeed, OAC treatment is not simply prescribing the drug (ie. warfarin), but paying attention to the quality of anticoagulation control, as reflected by the time in therapeutic range (TTR). 
Bleeding in the extreme elderly with OAC
Many studies have suggested that the major bleeding risk with OAC therapy is higher in older patients than in younger ones. Some studies have reported major bleeding rates with vitamin K antagonists in older patients of 1.1-5.1% per year [19] [20] [21] [22] [23] [24] . Another observational study reported a higher prevalence of 13.1% per year 25 . Our study showed that the incidence rate of major bleeding in the extreme elderly with OAC was only 1.8 per 100 person-years, and there was no significant difference compared with younger age strata. This could have been due to some of the extreme elderly who received OAC at enrollment stopping taking OAC at the follow-up. Alternatively, under-dosing of warfarin therapy may have decreased the risk of bleeding. Analysis of TTR should be used to assess the quality of warfarin control, but unfortunately we do not have data on TTR in this study.
Benefit-risk balance of OAC in extreme elderly patients with AF
Several recent studies have demonstrated that OAC therapy provides a net clinical benefit in the 
Study limitations
This study has several limitations. First, this is an observational study and provides only associative evidence, not causative. Second, OAC data were collected only at the time of entry into the study, so we were unable to explore the relationship between changes in OAC and clinical events.
Third, we investigated neither the TTR for patients taking warfarin during follow-up nor the adherence of OAC therapies, and therefore it would be difficult to know how the quality of warfarin control and the adherence of OAC therapies influenced outcomes. Fourth, about 10% of patients were missed during follow-up. As shown in the Supplementary Table, the population with 'missing data' was older, more often female, and had a higher CHADS 2 score than the followed patients, which could induce a selection bias. Finally, this study was conducted in Japanese AF patients, and it is uncertain whether the study results can be generalizable to other populations.
Conclusions
Our community-based large prospective cohort shows that Japanese extreme elderly patients with AF had a higher incidence of stroke, but similar major bleeding risk, compared with a younger AF population. Particular care is therefore needed when managing this elderly patient age group, given their high stroke risk overall. The log-rank test for incidence rates were performed.
SE: systemic embolism, HR: hazard ratio, CI: confidence interval.
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